10-Q: Vystar Corp. Reports Q2 2026 Results Amidst Financial Concerns

Vystar Corporation's Q2 2026 Form 10-Q filing reveals a significant revenue decrease and continued net losses, raising substantial doubt about its going concern status.

Summary

• Vystar Corporation reported a net loss of $225,293 for the three months ended June 30, 2026, compared to a loss of $426,732 for the same period in 2025.
• For the six months ended June 30, 2026, the net loss was $590,072, compared to $965,014 in the prior year.
• Revenue for the three months ended June 30, 2026, decreased by 33.1% to $7,767 from $11,615 in 2025.
• Revenue for the six months ended June 30, 2026, decreased by 42.7% to $13,914 from $24,272 in 2025.
• The company has substantial doubt about its ability to continue as a going concern due to a history of losses and negative cash flow.
• Management plans to finance future operations through cash on hand, increased revenue from RxAir and Vytex, stock issuances, and exploring M&A opportunities.
• Material weaknesses in internal control over financial reporting were identified, including lack of segregation of duties and insufficient control over records.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the company's continued significant losses, substantial doubt about its ability to continue as a going concern, and a sharp decline in revenue.

Positives

• Gross profit increased by 14.2% to $7,288 for the three months ended June 30, 2026, compared to $6,382 in the prior year.
• Gross profit increased by 8.1% to $11,560 for the six months ended June 30, 2026, compared to $10,689 in the prior year.
• Cost of revenue decreased significantly by 90.8% for the three months and 82.7% for the six months ended June 30, 2026, compared to the prior year periods.
• Total operating expenses decreased by 36.4% for the three months and 26.1% for the six months ended June 30, 2026, compared to the prior year periods.
• Other expense decreased by 63.4% for the three months and 59.4% for the six months ended June 30, 2026, due to reduced amortization and a gain on debt settlement.

Negatives

• Revenue declined significantly, down 33.1% for the quarter and 42.7% for the six-month period.
• The company continues to incur substantial net losses, with a loss of $225,293 for the quarter and $590,072 for the six months.
• There is substantial doubt about the company's ability to continue as a going concern.
• Working capital deficit of approximately $7.2 million as of June 30, 2026.
• Accumulated deficit reached approximately $62 million as of June 30, 2026.
• Material weaknesses in internal control over financial reporting were identified.
• The RX3000 Commercial FDA cleared Class II Air Purifier is currently not in production.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Failure to achieve projected revenue levels or secure additional financing could lead to significant curtailment of operations, bankruptcy, or cessation of operations.
• Tariffs by the U.S. government may impact future production and cost of products sold.
• The company is dependent on a single major customer for a significant portion of its sales.
• The company is subject to legal proceedings, including an ongoing appeal related to a breach of contract claim.
• Material weaknesses in internal control over financial reporting could lead to misstatements in financial reporting.

Future Outlook

Management plans to finance future operations using cash on hand, increased revenue from RxAir air purification units and Vytex license fees, common stock subscription issuances, and exploring merger and acquisition opportunities. However, there is substantial doubt about the company's ability to continue as a going concern if projected revenue is not achieved or additional financing is not secured.

Management Comments

• Management plans to finance future operations using cash on hand, increased revenue from RxAir air purification units and Vytex license fees, common stock subscription issuances, and exploring merger and acquisition opportunities.
• There can be no assurances that we will be able to achieve projected levels of revenue in 2026 and beyond.
• If we are not able to achieve projected revenue and obtain alternate additional financing of equity or debt, we would need to significantly curtail or reorient operations during 2026, which could have a material adverse effect on our ability to achieve our business objectives, and as a result, may require the Company to file bankruptcy or cease operations.

Industry Context

StockSavvy.ai notes that Vystar operates in the air purification and natural rubber latex markets. The air purification market is competitive, with a growing demand for products that can effectively eliminate viruses and bacteria. The natural rubber latex market is influenced by global supply chains and demand from various industries. Vystar's focus on patented technologies like ViraTech and Vytex aims to differentiate its offerings.

Comparison to Industry Standards

• The company's revenue of $7,767 for the quarter is significantly lower than established players in the air purification market, which often report millions in quarterly revenue.
• The substantial accumulated deficit of $62 million indicates a prolonged period of unprofitability, which is not sustainable for most companies in the consumer goods sector without significant external funding.
• The company's reliance on a single major customer for a significant portion of its sales (33% in the six months ended June 30, 2026) is a risk factor compared to diversified revenue streams common among larger, more stable companies in related industries.

Corporate Governance

Legal Proceedings

• EMA Financial, Inc. lawsuit alleging breaches of a convertible promissory note and stock purchase agreement. The company has been awarded legal fees, but an appeal is pending.
• The company is pursuing all available legal remedies to recover the outstanding balance and accrued interest from EMA Financial.

Related Party Transactions

• Stock subscription payable balance of $2,860,848 related to common and preferred stock to be issued to Jamie Rotman.
• Consulting agreement with Blue Oar Consulting, Inc. (owned by Gregory Rotman, brother of CEO Jamie Rotman), with payments temporarily suspended.
• Stock subscription payable balance of $1,182,930 related to common stock to be issued to Blue Oar Consulting, Inc.
• Steven Rotman has a stock subscription payable balance of $427,933 and $243,155 in reimbursable expenses payable.
• Related party advances totaling $77,460 due to Steven Rotman from Vystar.

Stakeholder Impact

• Shareholders: Continued losses and doubt about going concern status pose significant risk to shareholder value. Potential dilution from future stock issuances.
• Creditors: The company's financial condition raises concerns about its ability to meet its obligations.
• Employees: Uncertainty about the company's future could impact job security.
• Suppliers: Potential for delayed payments due to the company's liquidity challenges.

Next Steps

• The Company will continue to review its pricing and sales strategies in the third quarter of 2026.
• Management plans to finance future operations using cash on hand, increased revenue from RxAir air purification units and Vytex license fees, common stock subscription issuances, and exploring merger and acquisition opportunities.
• The company is pursuing all available legal remedies to recover the outstanding balance and accrued interest from EMA Financial.
• Vystar Corporation has entered into a joint venture with Capital Realm, Inc. to acquire a 50% interest each in r3alm, Inc.

Key Dates

Recommendation

The company exhibits significant financial distress, characterized by declining revenues, persistent net losses, a substantial accumulated deficit, and substantial doubt about its ability to continue as a going concern. The identified material weaknesses in internal controls further exacerbate these concerns. While there are ongoing efforts to secure financing and explore new ventures, the current financial trajectory and operational challenges present a high risk for investors.

Keywords

air purification, natural rubber latex, Vytex, RxAir, ViraTech, convertible notes, stock subscription, going concern